{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:11:19Z","timestamp":1792714279368,"version":"4.5.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA089961"],"award-info":[{"award-number":["R21CA089961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA058223"],"award-info":[{"award-number":["P50CA058223"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Previous work from our group and others has shown that patients with breast cancer can generate a T cell response against specific human epidermal growth factor 2 (HER2) epitopes. In addition, preclinical work has shown that this T cell response can be augmented by Ag-directed mAb therapy. This study evaluated the activity and safety of a combination of dendritic cell (DC) vaccination given with mAb and cytotoxic therapy. We performed a phase I\/II study using autologous DCs pulsed with two different HER2 peptides given with trastuzumab and vinorelbine to a study cohort of patients with HER2-overexpressing and a second with HER2 nonoverexpressing metastatic breast cancer. Seventeen patients with HER2-overexpressing and seven with nonoverexpressing disease were treated. Treatment was well tolerated, with one patient removed from therapy because of toxicity and no deaths. Forty-six percent of patients had stable disease after therapy, with 4% achieving a partial response and no complete responses. Immune responses were generated in the majority of patients but did not correlate with clinical response. However, in one patient, who has survived &amp;gt;14 y since treatment in the trial, a robust immune response was demonstrated, with 25% of her T cells specific to one of the peptides in the vaccine at the peak of her response. These data suggest that autologous DC vaccination when given with anti-HER2\u2013directed mAb therapy and vinorelbine is safe and can induce immune responses, including significant T cell clonal expansion, in a subset of patients.<\/jats:p>","DOI":"10.4049\/jimmunol.2300077","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T13:17:22Z","timestamp":1684502242000},"page":"219-228","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors"],"prefix":"10.1093","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-2282","authenticated-orcid":false,"given":"Benjamin G","family":"Vincent","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina , Chapel Hill, NC"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall , Chapel Hill, NC"},{"name":"Program in Computational Medicine, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1841-520X","authenticated-orcid":false,"given":"Danielle M","family":"File","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-5626","authenticated-orcid":false,"given":"Karen P","family":"McKinnon","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-8556","authenticated-orcid":false,"given":"Dominic T","family":"Moore","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Frelinger","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bixby","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Reisdorf","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia J","family":"Laurie","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara A","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-4074","authenticated-orcid":false,"given":"Carey K","family":"Anders","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A","family":"Collichio","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2862-9970","authenticated-orcid":false,"given":"Hyman B","family":"Muss","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"Lisa A","family":"Carey","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik W","family":"van Deventer","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina , Chapel Hill, NC"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Claire","family":"Dees","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Oncology, Department of Medicine, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-1092","authenticated-orcid":false,"given":"Jonathan S","family":"Serody","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina , Chapel Hill, NC"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall , Chapel Hill, NC"},{"name":"Program in Computational Medicine, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"2025020406015664400_r1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2025020406015664400_r2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2025020406015664400_r3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"2025020406015664400_r4","doi-asserted-by":"crossref","first-page":"PD8-02","DOI":"10.1158\/1538-7445.SABCS21-PD8-02","article-title":"Abstract PD8-02: trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY)","volume":"82","author":"Di\u00e9ras","year":"2022","journal-title":"Cancer Res."},{"key":"2025020406015664400_r5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-08-1126","article-title":"The impact of HER2\/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. [Published erratum appears in 2009 Clin. Cancer Res. 15: 5601.]","volume":"15","author":"Benavides","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2025020406015664400_r6","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"2025020406015664400_r7","doi-asserted-by":"crossref","first-page":"66192","DOI":"10.18632\/oncotarget.11751","article-title":"Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence","volume":"7","author":"Mittendorf","year":"2016","journal-title":"Oncotarget"},{"key":"2025020406015664400_r8","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1245\/s10434-017-5844-0","article-title":"Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients","volume":"24","author":"Clifton","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"2025020406015664400_r9","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase iii clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2025020406015664400_r10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","author":"Brown","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"2025020406015664400_r11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol."},{"key":"2025020406015664400_r12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00262-013-1489-4","article-title":"HER-2\/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2\/neu expressing cancers","volume":"63","author":"Disis","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"2025020406015664400_r13","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.1997.15.11.3363","article-title":"High-titer HER-2\/neu protein-specific antibody can be detected in patients with early-stage breast cancer","volume":"15","author":"Disis","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r14","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2002.06.171","article-title":"Generation of T-cell immunity to the HER-2\/neu protein after active immunization with HER-2\/neu peptide-based vaccines","volume":"20","author":"Disis","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r15","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1084\/jem.181.6.2109","article-title":"Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines","volume":"181","author":"Fisk","year":"1995","journal-title":"J. Exp. Med."},{"key":"2025020406015664400_r16","doi-asserted-by":"crossref","first-page":"36422","DOI":"10.1074\/jbc.274.51.36422","article-title":"Poor binding of a HER-2\/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide","volume":"274","author":"Kuhns","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2025020406015664400_r17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0198-8859(96)00292-3","article-title":"Identification of Her-2\/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8","volume":"52","author":"Lustgarten","year":"1997","journal-title":"Hum. Immunol."},{"key":"2025020406015664400_r18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/978-1-4757-9966-8_94","article-title":"Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2\/neu oncogene products using ex-vivo peptide loaded dendritic cells","volume":"417","author":"Navabi","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"2025020406015664400_r19","first-page":"3569","article-title":"HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice","volume":"60","author":"Reilly","year":"2000","journal-title":"Cancer Res."},{"key":"2025020406015664400_r20","first-page":"4902","article-title":"Immunization with a peptide epitope (p369-377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors","volume":"58","author":"Zaks","year":"1998","journal-title":"Cancer Res."},{"key":"2025020406015664400_r21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0065-2776(08)60023-1","article-title":"Dendritic cells","volume":"72","author":"Bell","year":"1999","journal-title":"Adv. Immunol."},{"key":"2025020406015664400_r22","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V90.9.3245","article-title":"Dendritic cells: unique leukocyte populations which control the primary immune response","volume":"90","author":"Hart","year":"1997","journal-title":"Blood"},{"key":"2025020406015664400_r23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/978-1-4757-9966-8_91","article-title":"Dendritic cell based therapy of cancer","volume":"417","author":"Lotze","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"2025020406015664400_r24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/89863","article-title":"Dendritic cells: on the move from bench to bedside","volume":"7","author":"Nestle","year":"2001","journal-title":"Nat. Med."},{"key":"2025020406015664400_r25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/icb.1997.35","article-title":"The role of dendritic cells in T cell activation","volume":"75","author":"Ni","year":"1997","journal-title":"Immunol. Cell Biol."},{"key":"2025020406015664400_r26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.186.8.1183","article-title":"Dendritic cells as adjuvants for immune-mediated resistance to tumors","volume":"186","author":"Schuler","year":"1997","journal-title":"J. Exp. Med."},{"key":"2025020406015664400_r27","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V86.7.2699.2699","article-title":"Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro","volume":"86","author":"Mackensen","year":"1995","journal-title":"Blood"},{"key":"2025020406015664400_r28","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood.V88.7.2541.bloodjournal8872541","article-title":"In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type","volume":"88","author":"Herbst","year":"1996","journal-title":"Blood"},{"key":"2025020406015664400_r29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1046\/j.1365-2141.1997.4283238.x","article-title":"CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis","volume":"99","author":"Herbst","year":"1997","journal-title":"Br. J. Haematol."},{"key":"2025020406015664400_r30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/360258a0","article-title":"GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells","volume":"360","author":"Caux","year":"1992","journal-title":"Nature"},{"key":"2025020406015664400_r31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.V90.4.1458","article-title":"CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis","volume":"90","author":"Caux","year":"1997","journal-title":"Blood"},{"key":"2025020406015664400_r32","doi-asserted-by":"crossref","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","article-title":"Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis","volume":"6","author":"Draube","year":"2011","journal-title":"PLoS One"},{"key":"2025020406015664400_r33","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"2025020406015664400_r34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/(SICI)1097-0045(19970901)32:4<272::AID-PROS7>3.0.CO;2-L","article-title":"Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides","volume":"32","author":"Tjoa","year":"1997","journal-title":"Prostate"},{"key":"2025020406015664400_r35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V","article-title":"Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease","volume":"38","author":"Murphy","year":"1999","journal-title":"Prostate"},{"key":"2025020406015664400_r36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"2025020406015664400_r37","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"key":"2025020406015664400_r38","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1084\/jem.190.11.1669","article-title":"Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma","volume":"190","author":"Thurner","year":"1999","journal-title":"J. Exp. Med."},{"key":"2025020406015664400_r39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/1084978042484759","article-title":"Phase I\/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis","volume":"19","author":"Dillman","year":"2004","journal-title":"Cancer Biother. Radiopharm."},{"key":"2025020406015664400_r40","first-page":"311","article-title":"Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report","volume":"24","author":"Dillman","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"2025020406015664400_r41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CJI.0b013e31826f79c8","article-title":"Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma","volume":"35","author":"Dillman","year":"2012","journal-title":"J. Immunother."},{"key":"2025020406015664400_r42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"2025020406015664400_r43","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-16-1924","article-title":"Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial","volume":"23","author":"Lowenfeld","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2025020406015664400_r44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3389\/fimmu.2019.01079","article-title":"Autologous hematopoietic stem cells are a preferred source to generate dendritic cells for immunotherapy in multiple myeloma patients","volume":"10","author":"Shinde","year":"2019","journal-title":"Front. Immunol."},{"key":"2025020406015664400_r45","first-page":"1099","article-title":"Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood","volume":"55","author":"Bernhard","year":"1995","journal-title":"Cancer Res."},{"key":"2025020406015664400_r46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41401-020-0415-5","article-title":"Ex vivo pulsed dendritic cell vaccination against cancer","volume":"41","author":"Gu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"2025020406015664400_r47","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood-2004-07-2809","article-title":"Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses","volume":"105","author":"Merck","year":"2005","journal-title":"Blood"},{"key":"2025020406015664400_r48","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.4049\/jimmunol.170.4.1641","article-title":"Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells","volume":"170","author":"Akiyama","year":"2003","journal-title":"J. Immunol."},{"key":"2025020406015664400_r49","doi-asserted-by":"crossref","first-page":"1703449","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"OncoImmunology"},{"key":"2025020406015664400_r50","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025020406015664400_r51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djs033","article-title":"Therapeutic cancer vaccines: current status and moving forward","volume":"104","author":"Schlom","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"2025020406015664400_r52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"2025020406015664400_r53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1470-2045(06)70985-8","article-title":"Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited","volume":"8","author":"Gabrilovich","year":"2007","journal-title":"Lancet Oncol."},{"key":"2025020406015664400_r54","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1158\/1078-0432.CCR-04-0497","article-title":"Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination","volume":"10","author":"Wheeler","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2025020406015664400_r55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"2025020406015664400_r56","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2025020406015664400_r57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2025020406015664400_r58","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.1994.12.10.2094","article-title":"Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study","volume":"12","author":"Gasparini","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.annonc.a058873","article-title":"Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer","volume":"5","author":"Degardin","year":"1994","journal-title":"Ann. Oncol."},{"key":"2025020406015664400_r60","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1995.13.11.2722","article-title":"Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer","volume":"13","author":"Weber","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r61","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2002.20.1.37","article-title":"Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer","volume":"20","author":"Stathopoulos","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"2025020406015664400_r63","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.4049\/jimmunol.0903931","article-title":"Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice","volume":"184","author":"Vincent","year":"2010","journal-title":"J. Immunol."},{"key":"2025020406015664400_r64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/2326-6066.CIR-14-0001","article-title":"Peptide\/MHC tetramer-based sorting of CD8+ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire","volume":"3","author":"Hunsucker","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"2025020406015664400_r65","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/ncomms3333","article-title":"IMGT\/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"issue":"D1","key":"2025020406015664400_r66","doi-asserted-by":"crossref","first-page":"D1262","DOI":"10.1093\/nar\/gkab1136","article-title":"IMGT\u00ae databases, related tools and web resources through three main axes of research and development","volume":"50","author":"Manso","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"2025020406015664400_r67","volume-title":"R: A language and environment for statistical computing.","author":"R Core Team","year":"2018"},{"key":"2025020406015664400_r68","article-title":"survminer: drawing survival curves using \u2018ggplot2\u2019","author":"Kassambara","year":"2021"},{"key":"2025020406015664400_r69","author":"Wickham","year":"2016"},{"key":"2025020406015664400_r70","article-title":"Rvision: colorblind-friendly color maps for R","author":"Garnier","year":"2021"},{"key":"2025020406015664400_r71","first-page":"1","article-title":"The igraph software package for complex network research","volume-title":"InterJournal. Complex Syst.","author":"Csardi","year":"2006"},{"key":"2025020406015664400_r72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0976-500X.72352","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"1","author":"Schulz","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"key":"2025020406015664400_r73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2025020406015664400_r74","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00262-004-0520-1","article-title":"Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer","volume":"53","author":"Dees","year":"2004","journal-title":"Cancer Immunol. Immunother."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/211\/2\/219\/61472782\/ji2300077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/211\/2\/219\/61472782\/ji2300077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:02:20Z","timestamp":1738648940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/211\/2\/219\/7925045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2300077","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,5,19]]}}}